Regeneron Pharmaceuticals, Inc.

Other

Regeneran Pharmaceuticals, Inc.

Regeneron Pharmacueticals, Inc.

Samuel H Davis

George D Yancopoulos

Eric L Smith

Nicholas J Papadopoulos

Supriya Patel

Tong Zhang

Andrew J Murphy

Thomas H Aldrich

Erica Pyles

Pamela F Jones

Nina Liu

Michael Rosconi

Douglas MacDonald

Chia-Yang Lin

Kara Olson

Mark E Furth

Mitchell Goldfarb

Stephen P Squinto

Peter C Maisonpierre

Czeslaw Radziejewski

Joanne Bruno

Gavin Thurston

Jesper Gromada

Jessica Kirshner

Eric B Smith

Haruka Okamoto

Bindu Varghese

Nicholas W Gale

Yang Wei

David M Valenzuela

Aris N Economides

Jiaxi Wu

Nicolin Bloch

Lynn Macdonald

Sean Stevens

Neil E Stahl

Israel Lowy

Robert Babb

Christopher Daly

Ashique Rafique

Karolina A Hosiawa

John Mcwhirter

David R Buckler

Carrie Brownstein

Chiayang Lin

Karolina A Meagher

Jessica R Kirshner

Kara Louise Olson

Eric Smith

Antigen binding molecules (ABMs) comprising Fab domains in non-native configurations, ABM conjugates comprising the ABMs and cytotoxic or cytostatic agents, pharmaceutical compositions containing the ABMs and ABM conjugates, methods of using the ABMs, ABM conjugates and pharmaceutical compositions for treating cancer, nucleic acids encoding the ABMs, cells engineered to express the ABMs, and methods of producing ABMs.

Antigen binding molecule formats

This disclosure relates to IL-2 variants and methods of use thereof, including methods of treating or inhibiting a cancer or tumor. The IL-2 variants may have reduced ability in binding to or activating IL-2Rα. The IL-2 variants may retain the ability in binding to or activating IL-2Rβ and/or IL-2Rγ. In addition, the IL-2 variants may have decreased Treg activity but maintain the capacity to activate NK cells and T effector cells.

Il-2 variants with reduced binding to IL-2 receptor alpha and uses thereof

A bispecific antibody format providing ease of isolation is provided, comprising immunoglobulin heavy chain variable domains that are differentially modified in the CH3 domain, wherein the differential modifications are non-immunogenic or substantially non-immunogenic with respect to the CH3 modifications, and at least one of the modifications results in a differential affinity for the bispecific antibody for an affinity reagent such as Protein A, and the bispecific antibody is isolable from a disrupted cell, from medium, or from a mixture of antibodies based on its affinity for Protein A.

Readily isolated bispecific antibodies with native immunoglobulin format

The present invention provides modified glucagon-like peptide 1 (GLP1) polypeptides, fusion proteins comprising modified GLP1 polypeptides, and methods of use thereof. In various embodiments of the invention, the fusion proteins are GLP1 receptor agonists that comprise a modified GLP1 fused to a stabilizing domain. In some embodiments, the fusion proteins comprising modified GLP1 are useful for treating or ameliorating a symptom or indication of a disorder such as obesity and diabetes.

Glucagon-like peptide 1 receptor agonists and uses thereof

This disclosure relates to IL-2 variants and methods of use thereof, including methods of treating or inhibiting a cancer or tumor. The IL-2 variants may have reduced ability in binding to or activating IL-2R&#x3b1;. The IL-2 variants may retain the ability in binding to or activating IL-2R&#x3b2; and/or IL-2R&#x3b2;&#x3b3;. In addition, the IL-2 variants may have decreased Treg activity but maintain the capacity to activate NK cells and T effector cells.

IL-2 variants with reduced binding to IL-2 receptor alpha and uses thereof

The invention provides antibody heavy chain constant regions with a hinge region modified to reduce binding to Fc&#x3b3; receptors. The modification occurs within positions 233-236 by replacement of natural residues by glycine(s) and/or deletion(s). Such modifications can reduce binding of an antibody bearing such a constant region to Fc&#x3b3; receptors to background levels. The constant regions can be incorporated into any format of antibody or Fc fusion protein. Such antibodies or fusion proteins can be used in methods of treatment, particularly those in which the mechanisms of action of the antibody or Fc fusion protein is not primarily or at all dependent on effector functions, as is the case when an antibody inhibits a receptor-ligand interaction or agonizes a receptor.

Heavy chain constant regions with reduced binding to Fc gamma receptors

The present invention provides bispecific antibodies that bind to CD3 and tumor antigens and methods of using the same. According to certain embodiments, the bispecific antibodies of the invention exhibit reduced effector functions and have a unique binding profile with regard to Fc&#x3b3; receptors. The bispecific antibodies are engineered to efficiently induce T cell-mediated killing of tumor cells. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3, a second antigen-binding molecule that specifically binds human CD20, and an Fc domain that binds Fc&#x3b3; receptors with a specific binding pattern. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of B-cell or melanoma tumors expressing CD20. The bispecific antibodies of the invention are useful for the treatment of various cancers as well as other CD20-related diseases and disorders.

Methods and antibody compositions for tumor treatment

Growing community of inventors

Jericho, NY, United States of America

Samuel H Davis